Product Details
| Product Name:
Ofatumumab |
CAS No.:
679818-59-8 |
| Purity:
99.0% (SEC-HPLC) |
Supply Ability:
10g |
| Release date:
2025/09/11 |
Product Introduction
Bioactivity
| Name | Ofatumumab |
| Description | Ofatumumab is a fully human monoclonal antibody to CD20 which appears to inhibit early-stage B lymphocyte activation |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | selective | Ofatumumab | lysing B cells | Inhibitor | inhibit | FcR | cytotoxicity | chronic lymphocytic leukaemia | Arzerra | anti-CD20 monoclonal antibody |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:223104-29-8
$74.00 / 5mg
-
CAS:5355-16-8
$33.00 / 500mg
-
CAS:1339058-04-6
$38.00 / 5mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States